Latest News in the pharma Industry

Research & Development

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin

20 Nov 2016

BI 695502 met all the pre-defined primary and secondary endpoints in the INVICTAN-1 study.

Read more 
CSL Behring presents positive results from CSL112 Phase IIb trial

CSL Behring presents positive results from CSL112 Phase IIb trial

16 Nov 2016

CSL112 is being developed to reduce the high incidence of early recurrent cardiovascular events.

Read more 
Repatha regresses atherosclerosis in patients with coronary artery disease

Repatha regresses atherosclerosis in patients with coronary artery disease

15 Nov 2016

Nearly two-thirds of patients experienced plaque regression with Repatha on top of optimized statin therapy.

Read more 
GSK announces positive results in fourth consecutive pivotal trial of Benlysta in SLE

GSK announces positive results in fourth consecutive pivotal trial of Benlysta in SLE

14 Nov 2016

Data in Japan, China and South Korea will form basis of new regulatory submissions for Benlysta.

Read more 
Jardiance consistently reduced the risk of cardiovascular death in adults with type 2 diabetes

Jardiance consistently reduced the risk of cardiovascular death in adults with type 2 diabetes

13 Nov 2016

Is the only oral type 2 diabetes medicine shown to reduce the risk of cardiovascular death.

Read more 
BMS's Opdivo is the first immuno-oncology treatment to receive FDA approval

BMS's Opdivo is the first immuno-oncology treatment to receive FDA approval

11 Nov 2016

Treatment proven in a Phase III trial to significantly extend overall survival for patients with recurrent or metastatic squamous cell head and neck cancer.

Read more 
Amgen and Janssen to co-fund studies with Kyprolis and Darzalex in patients with multiple myeloma

Amgen and Janssen to co-fund studies with Kyprolis and Darzalex in patients with multiple myeloma

10 Nov 2016

The first study initiated as part of this agreement is a Phase III registrational trial evaluating Kyprolis in combination with Darzalex and dexamethasone compared to Kyprolis and dexamethasone alone.

Read more 
New, rapid screening test identifies potential therapies against drug-resistant bacteria

New, rapid screening test identifies potential therapies against drug-resistant bacteria

9 Nov 2016

Screening method provides a potential new approach to repurpose known drugs and compounds.

Read more 
Mucosis initiates FiH study of SynGEM, a needle-free nasal spray RSV vaccine

Mucosis initiates FiH study of SynGEM, a needle-free nasal spray RSV vaccine

9 Nov 2016

Research has shown that boosting immunity in the nose and lungs may be the best way of increasing defence against RSV.

Read more 
Increased development of highly-targeted biologics set to change composition of asthma therapeutics market

Increased development of highly-targeted biologics set to change composition of asthma therapeutics market

9 Nov 2016

Biologics and monoclonal antibodies to become a bigger presence within the small-molecule-dominated landscape.

Read more 
AdAlta licenses Alzheimer's disease-specific shark antibodies to Crossbeta Biosciences

AdAlta licenses Alzheimer's disease-specific shark antibodies to Crossbeta Biosciences

8 Nov 2016

These shark antibodies are considered to have immediate and highly disease-specific potential for the diagnosis and treatment of Alzheimer’s disease.

Read more 
Testing of investigational inactivated Zika vaccine in humans begins

Testing of investigational inactivated Zika vaccine in humans begins

7 Nov 2016

First of five planned clinical trials to test ZPIV vaccine.

Read more